在晚期前列腺癌中,候选代孕终点的元分析
Laila A Gharzai1, Ralph Jiang2, Elizabeth M Jaworski3
1Department of Radiation Oncology, Northwestern University, Chicago.
NEJM evidence
|February 6, 2024
概括
通常使用的临床终点不是高级前列腺癌的整体存活率的有效替代品. 这项研究发现,没有替代终点符合预测晚期前列腺癌患者整体存活率的标准.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 无转移存活率是局部性前列腺癌整体存活率 (OS) 的验证替代品.
- 目前对于晚期前列腺癌 (PC) 没有经过验证的代孕终点.
结论:
- 通常使用的临床终点并不是在晚期前列腺癌中整体存活的有效替代品.
- 这种综合查方法凸显了对高级PC临床试验可靠代用终点的进一步研究的需要.
相关概念视频
Cancer Survival Analysis
348
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
348
Comparing the Survival Analysis of Two or More Groups
188
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
188


